RSV vaccines in vulnerable populations

Respiratory syncytial virus vaccines are safe and effective in vulnerable populations.

In a systematic review published in the Cochrane Database of Systematic Reviews, an international team of investigators examined the safety and efficacy outcomes of the RSV vaccines among more than 100,000 patients participating in 14 clinical trials.

The investigators discovered that vaccines were capable of protecting infants and older patients most at risk of severe disease and mortality. For instance, prefusion vaccines decreased the likelihood of RSV-associated lower respiratory tract disease and RSV-associated acute respiratory disease among older patients and RSV F protein-based vaccines mitigated the risk of severe RSV-related disease among the children of mothers vaccinated during pregnancy. There were no statistically significant differences in adverse events between those who received or didn’t receive RSV vaccines.

Read more: Cochrane Database of Systematic Reviews

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.